COVID-19
Séquelles post-COVID - Nouveautés
1-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals

- SARS-CoV-2 positive: 19.8% persistent symptoms, 33.4% functional impairment
- SARS-CoV-2 negative: 80.2% persistent symptoms, 6.5% functional impairment

Persistent symptoms:
- Fatigue
- Loss or change in smell
- Loss or change in taste
- Dyspnea
- Headache
- Insomnia
- Difficulty concentrating
- Mental exhaustion
- Paresthesia
- Dizziness
- Cough
- Chest pain
- Palpitations
- Myalgia
- Arthralgia
- Digestive symptoms

Functional impairment:
- Professional
- Social
- Family life

n=1,447

Estimates of symptoms prevalence and functional impairment in healthcare workers compared to the general population, and in SARS-CoV-2 positive and negative healthcare workers

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Healthcare workers (n=3,083)</th>
<th>General population (n=3,556)</th>
<th>P-value</th>
<th>Healthcare workers (n=3,083)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 positive (n=1,079)</td>
<td></td>
<td></td>
<td></td>
<td>SARS-CoV-2 negative (n=2,004)</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>25.8 (25.0-26.0)</td>
<td>5.5 (5.3-5.6)</td>
<td>&lt;0.001</td>
<td>32.5 (31.7-3.2)</td>
<td>21.4 (20.9-21.9)</td>
</tr>
<tr>
<td>Headache</td>
<td>10.0 (9.7-10.3)</td>
<td>3.4 (3.3-3.5)</td>
<td>&lt;0.001</td>
<td>13.3 (12.7-13.9)</td>
<td>7.8 (7.4-8.1)</td>
</tr>
<tr>
<td>Difficulty concentrating/Loss of memory</td>
<td>7.9 (7.6-8.2)</td>
<td>2.6 (2.3-2.7)</td>
<td>&lt;0.001</td>
<td>13.4 (12.9-14.0)</td>
<td>4.6 (4.4-4.8)</td>
</tr>
<tr>
<td>Exhaustion/Burnout</td>
<td>7.1 (6.9-7.4)</td>
<td>1.8 (1.7-1.9)</td>
<td>&lt;0.001</td>
<td>9.2 (8.8-9.6)</td>
<td>6.3 (6.0-6.5)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6.7 (6.5-6.9)</td>
<td>1.3 (1.2-1.4)</td>
<td>&lt;0.001</td>
<td>7.9 (7.5-8.3)</td>
<td>5.4 (5.1-5.6)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>6.7 (6.5-6.9)</td>
<td>2.3 (2.3-2.4)</td>
<td>&lt;0.001</td>
<td>8.9 (8.5-9.4)</td>
<td>6.3 (6.0-6.5)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>6.7 (6.5-6.9)</td>
<td>1.4 (1.3-1.5)</td>
<td>&lt;0.001</td>
<td>8.0 (7.6-8.6)</td>
<td>5.5 (5.2-5.8)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>5.2 (4.9-5.4)</td>
<td>2.2 (2.1-2.4)</td>
<td>&lt;0.001</td>
<td>12.0 (11.2-12.8)</td>
<td>2.6 (2.4-2.8)</td>
</tr>
<tr>
<td>Loss or change in smell</td>
<td>7.2 (6.8-7.6)</td>
<td>5.8 (5.5-6.0)</td>
<td>&lt;0.001</td>
<td>17.3 (16.6-17.9)</td>
<td>1.7 (1.5-1.8)</td>
</tr>
</tbody>
</table>

CoviCare group
Estimates of symptoms prevalence and functional impairment in healthcare workers compared to the general population, and in SARS-CoV-2 positive and negative healthcare workers

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Healthcare workers (n=3,083)</th>
<th>General population (n=3,556)</th>
<th>P-value</th>
<th>Healthcare workers (n=3,083)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SARS-CoV-2 positive (n=1,079)</td>
<td>SARS-CoV-2 negative (n=2,004)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>25.5 (25.0-26.0)</td>
<td>5.5 (5.3-5.6)</td>
<td>&lt;0.001</td>
<td>32.5 (31.7-3.2)</td>
<td>21.4 (20.9-21.9)</td>
</tr>
<tr>
<td>Headache</td>
<td>10.0 (9.7-10.3)</td>
<td>3.4 (3.3-3.5)</td>
<td>&lt;0.001</td>
<td>13.3 (12.7-13.9)</td>
<td>7.8 (7.4-8.1)</td>
</tr>
<tr>
<td>Difficulty concentrating/</td>
<td>7.9 (7.6-8.2)</td>
<td>2.6 (2.5-2.7)</td>
<td>&lt;0.001</td>
<td>13.4 (12.9-14.0)</td>
<td>4.6 (4.4-4.8)</td>
</tr>
<tr>
<td>Loss of memory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exhaustion/Burnout</td>
<td>7.1 (6.9-7.4)</td>
<td>1.8 (1.7-1.9)</td>
<td>&lt;0.001</td>
<td>9.2 (8.8-9.6)</td>
<td>6.3 (6.0-6.5)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6.2 (6.0-6.4)</td>
<td>1.2 (1.2-1.3)</td>
<td>&lt;0.001</td>
<td>7.8 (7.5-8.2)</td>
<td>5.3 (5.1-5.6)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>6.7 (6.5-6.9)</td>
<td>2.3 (2.3-2.4)</td>
<td>&lt;0.001</td>
<td>8.9 (8.5-9.4)</td>
<td>6.3 (6.0-6.5)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>6.3 (6.1-6.5)</td>
<td>1.4 (1.3-1.4)</td>
<td>&lt;0.001</td>
<td>8.8 (8.3-9.3)</td>
<td>5.5 (5.2-5.8)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>5.2 (4.9-5.4)</td>
<td>2.2 (2.1-2.4)</td>
<td>&lt;0.001</td>
<td>12.0 (11.2-12.8)</td>
<td>2.6 (2.4-2.8)</td>
</tr>
<tr>
<td>Loss or change in smell</td>
<td>7.2 (6.8-7.6)</td>
<td>5.8 (5.5-6.0)</td>
<td>&lt;0.001</td>
<td>17.3 (16.6-17.9)</td>
<td>1.7 (1.5-1.8)</td>
</tr>
</tbody>
</table>

CoviCare group

Adjusted frequency estimates of utilization of healthcare resources since test date, stratified by SARS-CoV-2 infection and duration of symptoms

Estimates were adjusted for age, sex, physical activity, smoking status, vaccination status, hospitalization, self-rated health prior to testing, symptoms at testing and the following comorbidities: obesity or overweight, hypertension, diabetes, respiratory disease, cardiovascular disease, headache disorders, cognitive disorders, sleep disorders, depression, anxiety, hypothyroidism, rheumatologic disease, anemia, chronic pain or fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome.

(n=1,383)

En pratique clinique

- Aménagement du quotidien – Identification et Pacing
- Ergothérapie
- Bilan neuropsychologique et suivi
- Soutien et encadrement
Prise en charge

Collaboration multicentrique et multidisciplinaire – Aspects médicaux, sociaux et professionnels

Colloques CoviBoard, coordination des soins

Consultation spécialisée: Évaluation complète et multidisciplinaire

Coordination par médecin traitant

Investigations, suivi par médecin traitant

Prise en charge par médecin traitant

Dépistage & Prise en charge

Prévention – Information – Echange citoyen.ne.s- communauté

Symptômes très invalidants, pas d’amélioration, complexité sociale ou médicale

Symptômes persistants fréquents ou multiples

Symptômes persistants

Population générale
RAFAEL, LA PLATEFORME D'INFORMATION POST-COVID

Informations générales
Informations santé
Informations générales pour les adultes et enfants suite à une infection au virus du Covid-19

Informations et diagnostic
Pour les adultes
Informations destinées aux adultes qui développent des symptômes persistants suite à une infection du Covid-19.

Informations et diagnostic
Pour les enfants
Informations destinées aux enfants qui ont des symptômes post-Covid ou Long Covid.
TRAITEMENTS PHARMACOLOGIQUES ET ESSAIS CLINIQUES DU POST-COVID

Sixième webinaire de la plateforme RAFAEL

Échangez avec le Pr Idiris Guessous, médecin-chef du Service de médecine de premier recours, HUG et le Pr Dominique Salmon, Université Paris-Descartes, Assistance publique hôpitaux de Paris (APHP).

Mercredi 28 septembre 2022 de 17h à 18h
En visioconférence

Gratuit sur inscription
https://rafael-postcovid.ch
Essai clinique

- Testé positif (PCR, Ag, sérologie)
- Fatigue/troubles de concentration
- Traitement (Temelimab) vs placebo
- 1 visite/mois sur 6 mois
Merci

Mayssam NEHME
mayssam.nehme@hcuge.ch

Idris GUESSOUS
idris.guessous@hcuge.ch

Service de Médecine de Premier Recours
Hôpitaux Universitaires de Genève